Improved overall survival in melanoma with combined dabrafenib and trametinib. [electronic resource]
Producer: 20150107Description: 30-9 p. digitalISSN:- 1533-4406
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Female
- Humans
- Imidazoles -- administration & dosage
- Indoles -- adverse effects
- Intention to Treat Analysis
- Kaplan-Meier Estimate
- Male
- Melanoma -- drug therapy
- Middle Aged
- Mitogen-Activated Protein Kinase Kinases -- antagonists & inhibitors
- Mutation
- Oximes -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Pyridones -- administration & dosage
- Pyrimidinones -- administration & dosage
- Skin Neoplasms -- drug therapy
- Sulfonamides -- adverse effects
- Survival Analysis
- Vemurafenib
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.